Advanced Laser Glaucoma Treatment: Making First-Line Therapy Accessible
Discover how next-generation laser technology is simplifying glaucoma care and changing treatment approaches for patients worldwide.
laser glaucoma treatment
The Shift Away from Daily Eye Drops
For decades, glaucoma patients have relied on daily eye drops as the first step in managing their condition. While these medications work for many people, they come with real challenges. Poor adherence to daily routines, ocular surface disease from chronic use, and the burden of long-term treatment have pushed eye care specialists to explore alternative approaches. The result is a fundamental transformation in how glaucoma is managed—one that increasingly prioritizes laser-based solutions over medications alone.
Why Laser Therapy Is Becoming the Preferred Starting Point
Selective Laser Trabeculoplasty (SLT) has emerged as a compelling first-line option, supported by robust clinical evidence. The landmark LiGHT Trial demonstrated that nearly 70% of eyes treated with SLT first—with six years of follow-up—remained free of drops without requiring glaucoma surgery. Importantly, disease progression occurred less frequently in patients who started with SLT compared to those initially managed with medications, with progression rates of 19.6% versus 26.8%, respectively.
The surgical benefits are also notable. Patients who underwent SLT required fewer trabeculectomies (13 cases or 2.4% versus 32 cases or 5.8% in the medication group) and fewer phacoemulsifications (57 versus 95 procedures). These findings suggest that early laser intervention may reduce the need for more invasive surgical procedures down the line.
Beyond the LiGHT Trial, research from the United Kingdom, Sweden, China, and other healthcare settings consistently demonstrates that SLT can provide long-term disease control without medications, with only occasional retreatment needed in many patients. The key advantage appears when SLT is introduced early in the disease course.
International Guidelines Now Support Laser-First Treatment
The clinical evidence has rapidly influenced practice standards worldwide. The American Academy of Ophthalmology, the European Glaucoma Society, and the UK’s NICE guidelines all now recognize SLT as an appropriate first-line treatment. NICE has gone further, explicitly recommending laser-first treatment for newly diagnosed patients whenever appropriate—a significant shift from the traditional medication-first approach.
The Real-World Barriers to SLT Adoption
Despite strong evidence and guideline support, conventional SLT has not become routine practice since its introduction in 1995. The procedure requires gonioscopy (visualization of the drainage angle using a special contact lens), topical anesthesia, and considerable operator experience. Accurate visualization of the drainage angle can be technically demanding and limits widespread adoption, even though SLT has proven efficacy, safety, and durability. Additionally, while some patients tolerate the procedure very well, others experience discomfort or difficulty with the contact lens positioning required for treatment.
These practical barriers have kept many practices from offering laser therapy as a first-line option, despite its clinical advantages.
A New Approach: Direct Selective Laser Trabeculoplasty
The Voyager Direct Selective Laser Trabeculoplasty (DSLT) system represents a significant technical innovation designed to overcome these barriers. Unlike conventional SLT, which requires a gonioscopy lens for visualization and treatment delivery, DSLT uses automated image guidance to deliver laser energy translimbally through the limbus—the border between the cornea and the white of the eye. This noncontact approach eliminates the need for a contact lens while still targeting the trabecular meshwork (the eye’s natural drainage system).
The procedure is remarkably efficient. DSLT completes treatment in approximately 2 to 3 seconds, creating what developers describe as a patient-centered experience. The average total energy delivered to the trabecular meshwork was lower for DSLT (21.7 mJ) compared to conventional SLT (28.5 mJ), suggesting a more targeted delivery approach. Patient satisfaction with the procedure reached 96%.
By eliminating the need for contact lens positioning and slit-lamp adjustments, DSLT streamlines the treatment process for both physicians and staff while being specifically designed for patient comfort. This simplified workflow has the potential to optimize practice efficiency and make laser-first therapy a more practical choice for everyday clinical settings.
Clinical Trial Results: The GLAUrious Study
A multicentre comparison study called GLAUrious examined how Voyager DSLT performed against conventional SLT in 192 patients with open-angle glaucoma or ocular hypertension. At 6 months, DSLT achieved a 20.6% intraocular pressure (IOP) reduction of 5.5 mmHg, compared to 23.6% (6.2 mmHg) with conventional SLT. While conventional SLT showed a slightly larger reduction, the difference was not clinically significant.
The real test came at 12 months. Both groups maintained similar medicated IOP reductions (approximately 3.2 mmHg), with comparable proportions of patients remaining medication-free. This durability is crucial because it suggests that DSLT offers sustained pressure control without requiring additional medications, matching the performance of the established SLT technique.
The study confirmed that Voyager DSLT provides effective treatment within modern glaucoma pathways, particularly where improving access to laser therapy is a priority. It demonstrated overall clinical efficiency, sustained pressure reduction, and a favorable safety profile.
What This Means for Glaucoma Patients
The emergence of easier-to-deliver laser technologies means more patients may have access to laser-first treatment earlier in their disease course. Instead of starting with daily eye drops—which require consistent adherence and can cause surface irritation—patients might begin with a brief, noncontact laser procedure that provides comparable or superior long-term outcomes.
For patients who struggle with remembering daily medications or who experience side effects from eye drops, this represents a meaningful alternative. The ability to potentially remain drop-free for years, with only occasional retreatment if needed, addresses one of the most frustrating aspects of glaucoma management.
It’s also worth noting that these benefits don’t require delaying treatment. Introducing laser therapy early, rather than waiting months or years on medications first, appears to provide better long-term disease control and may reduce the need for surgical intervention later.
When to Discuss Laser Treatment With Your Eye Doctor
If you’ve recently been diagnosed with glaucoma or ocular hypertension, ask your ophthalmologist whether laser-first therapy might be appropriate for you. This is especially relevant if you have concerns about daily medication adherence, experience side effects from eye drops, or have ocular surface disease.
During your consultation, your doctor will assess factors like your specific glaucoma type, baseline eye pressure, optic nerve health, and visual field status. They’ll also consider whether your drainage angle is suitable for laser treatment. If conventional SLT hasn’t been offered in your practice, ask whether newer noncontact laser systems like DSLT might be available or accessible through referral.
Regular monitoring remains essential regardless of your treatment choice. Even after successful laser therapy, your eye pressure and optic nerve need periodic assessment to ensure ongoing disease control. Schedule follow-up appointments as recommended by your ophthalmologist to catch any changes early.
